Oramed Pharmaceuticals Inc. (ORMP:NASDAQ) closed at $3.71 on November 13, 2026, down 7.94% on the day. The stock trades 32.2% below its 52-week high of $5.47 and 64.9% above its 52-week low of $2.25. Over the past year, it gained 59.2%. Oramed Pharmaceuticals Inc. is part of the Health Care sector (Major Pharmaceuticals).
In 252 trading sessions since November 13, 2025, ORMP closed higher on 121 days (48%). Its best day was June 25, 2026 (+16.28%) and its worst was May 22, 2026 (-8.90%). The stock moved 10% or more in a single session 3 times.
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the use of orally ingestible capsules or pills for delivery of polypeptides. Its product portfolio includes ORMD-0801, an oral insulin capsule, which has completed Phase IIb clinical trials for the treatment of diabetes; and ORMD-0901, an analog for GLP-1 gastrointestinal hormone, which has completed Phase Ib clinical trials for the treatment of type 2 diabetes. The company operates primarily in Israel. The company was formerly known as Integrated Security Technologies, Inc. and changed its name to Oramed Pharmaceuticals Inc. in April 2006. Oramed Pharmaceuticals Inc. was founded in 2002 and is based in Jerusalem, Israel.
Find more stocks like ORMP with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.